In 2012, ponatinib received authorization for use in patients with all phases CML and resistance or intolerance to dasatinib or nilotinib and for whom subsequent treatment with imatinib is not clinically appropriate or who have the gatekeeper BCR-ABL T315I mutation [12]. The gene discussed is ABL1; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.